文献速递肾癌与肾肿瘤

主动监测在局限性小肾肿块中的作用

Role of Active Surveillance for Localized Small Renal Masses.
PubMed 文献 · Eur Urol Oncol · 2018-05-26

该系统性综述检索Embase、Medline和Cochrane数据库,纳入28项研究,评估主动监测用于器官局限性肾肿块的风险权衡。临床局限性肾肿块中位线性肿瘤生长速率为0.37cm/年,转移进展率1-6%,2011牛津证据等级为3级。现有数据支持主动监测用于临床局限性肾肿块尤其是小肾肿块及老年和/或合并症患者的肿瘤学安全性。

要点

  • 临床局限性肾肿块中位线性生长速率0.37cm/年,cT1a为0.22cm/年,cT1b-2为0.45cm/年。
  • 转移进展率1-6%,cT1a为1-6%,cT1b为0-5%。
  • 主动监测作为临床局限性肾肿块治疗选择的证据水平为2011牛津量表3级。

核心结论

  • 尽管无随机临床数据,现有数据支持主动监测用于临床局限性肾肿块管理的肿瘤学安全性,尤其适用于小肾肿块及老年和/或合并症患者。

研究设计与样本

  • 系统性综述,检索Embase、Medline和Cochrane数据库,共纳入28项研究。

主要发现

  • 临床局限性肾肿块中位线性肿瘤生长速率为0.37cm/年(四分位距0.15-0.7),cT1a亚组为0.22cm/年,cT1b-2亚组为0.45cm/年。
  • 转移进展率为1-6%,cT1a为1-6%,cT1b为0-5%。
  • 临床局限性肾肿块患者其他原因死亡率为0-45%(cT1a为1-25%,cT1b-2为11-13%),癌症特异性死亡率范围为0%-18%。

关键数值与推荐

  • 根据2011牛津量表,主动监测作为临床局限性肾肿块治疗选择仍由3级证据支持。

临床怎么用

  • 患者总结指出,监测是小于2cm肿瘤的安全初始选择,尤其适用于老年和体弱患者。

局限性

  • 无随机临床数据可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Stage migration of organ-confined renal masses is occurring as a result of incidental diagnosis, especially in the elderly. Active surveillance (AS) is gaining clinical traction as a treatment alternative to surgery and focal therapy. OBJECTIVE: To assess contemporary data and evaluate AS risk trade-offs in the treatment of organ-confined kidney cancer. EVIDENCE ACQUISITION: A comprehensive search of the Embase, Medline and Cochrane databases was carried out. A systematic review of the role of AS for organ-confined renal masses was performed. A total of 28 studies were included in the systematic review. EVIDENCE SYNTHESIS: The median linear tumor growth rate for clinically localized renal masses (CLRMs) was 0.37cm/yr (interquartile range 0.15-0.7), with 0.22cm/yr in the cT1a subgroup and 0.45cm/yr in the cT1b--2 subgroup. The metastatic progression rate was 1-6% and was similar for cT1a (1-6%) and cT1b (0-5%); other-cause mortality for patients with CLRMs was 0-45% (1-25% for cT1a vs 11-13% for cT1b-2); cancer-specific mortality ranged between 0% and 18%. According to the 2011 Oxford scale, AS as a treatment option for CLRMs remains supported by level 3 evidence. CONCLUSIONS: Although no randomized clinical data are available, current data support oncologic safety for AS in the management of CLRMs, particularly for small renal masses and among elderly and/or comorbid patients. PATIENT SUMMARY: In this review we looked at the outcomes for patients with small kidney masses managed with surveillance. We found that surveillance is a safe initial option for tumors of less than 2cm, especially in elderly and sick patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mir MC, Capitanio U, Bertolo R, et al. Role of Active Surveillance for Localized Small Renal Masses. Eur Urol Oncol. 2018. PMID: 31102618. doi:10.1016/j.euo.2018.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。